[An Overview and Interpretation of Important Clinical Studies â©on Non-small Cell Lung Cancer in 2021].
Zhongguo Fei Ai Za Zhi
; 25(5): 295-302, 2022 May 20.
Article
in Chinese
| MEDLINE | ID: covidwho-1847419
ABSTRACT
Though the coronavirus disease is still raging in 2021, clinical research on non-small cell lung cancer (NSCLC) did not stop. However, benefiting from advances in lung cancer treatment modality, NSCLC patients have experienced significant improvements in overall survival and quality of life. Currently, research advances on targeted therapy and immunotherapy have together transformed the status of postoperative adjuvant therapy and established a new standard treatment modality for resectable NSCLC. There are equally important research advances in locally advanced and advanced NSCLC, including new treatment modalities, new therapeutic agents, etc., all of which bringing more options for clinical treatment. These therapies will bring changes to NSCLC and will gradually lead to the chronicity of lung cancer in the foreseeable future. Therefore, this paper reviews important studies that will change clinical practice in NSCLC treatment and noteworthy research advances in 2021.â©.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Zhongguo Fei Ai Za Zhi
Journal subject:
Neoplasms
Year:
2022
Document Type:
Article
Affiliation country:
J.issn.1009-3419.2022.101.19
Similar
MEDLINE
...
LILACS
LIS